Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Magnetic Resonance Imaging Contrast Agents Clear all
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

NCT01344447
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

NCT01211873
View directory record Official record
Conditions
Diagnostic Self Evaluation, Central Nervous System Diseases
Interventions
Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
2 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Imaging of Totally Blocked Arteries

NCT00459446
View directory record Official record
Conditions
Atherosclerosis, Peripheral Artery Disease, Intermittent Claudication, Chronic Total Aterial Occlusion
Interventions
MS-325 Injection (Gadofosveset Trisodium)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 10:59 AM EDT
Active, not recruiting No phase listed Observational

Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors

NCT00581906
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DCE-MRI, DW-MRI and MRS
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 26, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional Results available

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT00845702
View directory record Official record
Conditions
Renal Artery Stenosis
Interventions
Gadoterate meglumine (Dotarem), Time of Flight Magnetic Resonance Angiography
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 26, 2026, 10:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

NCT06262139
View directory record Official record
Conditions
MRI Scan
Interventions
MT218 injection
Drug
Lead sponsor
Songqi Gao
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging

NCT02311556
View directory record Official record
Conditions
Brain Metastases
Interventions
dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 4 Interventional

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

NCT00401687
View directory record Official record
Conditions
Ventricular Ejection Fraction
Interventions
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Sep 26, 2026, 10:59 AM EDT
Completed No phase listed Observational

Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer

NCT00071357
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 10:59 AM EDT
Terminated Not applicable Interventional Results available

Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer

NCT01303419
View directory record Official record
Conditions
Breast Cancer
Interventions
CE-BMRI, DE-CEDM
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
21 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 26, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gadolinium Retention in Human Bone Tissue in Pediatric Patients

NCT03337594
View directory record Official record
Conditions
Gadolinium, MultiHance, Dotarem, Magnetic Resonance Imaging, Gadolinium Retention
Interventions
Pre-operative MRI with Dotarem, Pre-operative MRI with MultiHance, Surgery
Drug · Procedure
Lead sponsor
Donna Roberts
Other
Eligibility
Up to 18 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

NCT02080312
View directory record Official record
Conditions
Meniere's Disease
Interventions
Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

NCT03173066
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Ferumoxytol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 26, 2026, 10:59 AM EDT
Not listed Not applicable Interventional

Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization

NCT03440554
View directory record Official record
Conditions
Prostate Cancer
Interventions
Whole Body Non-Contrast MRI
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging

NCT02702635
View directory record Official record
Conditions
Brain Injuries, Cerebrovascular Disorders
Interventions
DCE MRI of the brain
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Improving the Concentration of MR Contrast in the Arteries

NCT02155218
View directory record Official record
Conditions
Magnetic Resonance Angiography, Contrast Media
Interventions
Standard Injection Rate, Patient Tailored Injection Rate, gadolinium contrast
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Quantitative Imaging Biomarkers for Sarcoma

NCT02579980
View directory record Official record
Conditions
Sarcoma
Interventions
DCE and DWI MRI, Surgery
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

NCT04307186
View directory record Official record
Conditions
Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 26, 2026, 10:59 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

NCT07472491
View directory record Official record
Conditions
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 26, 2026, 10:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comprehensive Imaging of Perforator Vessels and Subcutaneous Vascular Network With No-Exogenous Contrast and Non-Ionizing-Radiation Magnetic Resonance Angiography

NCT03567018
View directory record Official record
Conditions
Perforator Flap Surgery
Interventions
MRI Scan
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 26, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

NCT05061979
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Interventions
BAY1747846
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 26, 2026, 10:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

NCT04831138
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
MRI with ASL, ASL-MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 26, 2026, 10:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist

NCT01836055
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
20 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 26, 2026, 10:59 AM EDT